BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

April 18, 2011 7:00 AM UTC

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) gained $1.83 (16%) to $13.09 on Friday after EMA's CHMP recommended approval of Bydureon exenatide once weekly to treat Type II diabetes. Amylin and Eli Lilly and Co. (NYSE:LLY) co-developed Bydureon, which uses drug delivery technology from Alkermes Inc. (NASDAQ:ALKS). Alkermes rose $0.59 to $14 on Friday and was up $0.93 on the week. Amylin was up $2.07 (19%) for the week.

Celgene Corp. (NASDAQ:CELG) was up $1.06 to $56.98 last week even though FDA began a safety review of multiple myeloma (MM) and myelodysplastic syndromes (MDS) drug Revlimid lenalidomide. The review was triggered by preliminary data that showed a potential increased risk for secondary malignancies associated with the cancer drug...